Clinical trial
A Randomized, Blinded, Positive Control Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Completed a Two-dose Primary Series of Inactivated Vaccine
NCT05396573 is registered in ClinicalTrials.gov with Walvax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Blinded, Positive Control Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Completed a Two-dose Primary Series of Inactivated Vaccine
- Lead sponsor
- Walvax Biotechnology Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- July 31, 2022
- Completion date
- July 31, 2023
- Enrollment
- 120 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.